Irbesartan and Hydrochlorothiazide Tablets 175mg (14X2/box)

• Dossier: Ctd
• Transport Package: Free
• Specification: 175mg
• Trademark: Sinolead
• Origin: China
• Model NO.: tablets

Product Description

 

 

Basic Info.

 

Generic Name	Irbesartan and Hydrochlorothiazide Tablets 175mg
Strength	175mg
Packing	14tabs/blister,2blisters/box
Origin	China

Component:
Acetaminophen 500mg

Character:

150mg/12.5mg: Light pink double convex oval film coating, notched.

Indications:

It is used to treat essential hypertension. This fixed-dose combination is indicated for the treatment of patients whose blood pressure is not effectively controlled by irbesartan or hydrochlorothiazide alone.
 

Usage and dosage:

This product is used once daily on an empty stomach or with meals to treat patients whose blood pressure is not effectively controlled by irbesartan or hydrochlorothiazide alone.

It is recommended that patients adjust a single ingredient, namely irbesartan or hydrochlorothiazide.

Direct conversion from single ingredient to fixed compound therapy may be considered in the following cases:

· The 150/12.5mg combination of this product can be used in patients who cannot effectively control blood pressure with hydrochlorothiazide or irbesartan 150mg alone.

· The 300/12.5mg combination of this product can be used in patients with irbesartan 300mg alone or patients with 150mg/12.5mg combination cannot effectively control blood pressure.

· The 300/25mg compound can be used in patients whose blood pressure cannot be controlled by ambonol 300mg/12.5mg.

A daily dose greater than irbesartan 300mg/ hydrochlorothiazide 25mg is not recommended. If necessary, this product can be combined with other blood pressure lowering drugs (see Drug interactions).

Matters needing attention:

Hypotension - hypovolemic patients: This compound is used in hypertensive patients with no other risk factors for hypotension and is rarely associated with symptomatic hypotension. Symptomatic hypotension may occur in patients with insufficient blood volume and sodium due to the use of strong diuretics, severe salt restriction in the diet, and diarrhea and vomiting. These conditions should be corrected before treatment with this compound.

Renal artery stenosis - Renal vascular hypertension: Patients with bilateral renal artery stenosis in a single functioning kidney who are treated with angiotensin-converting enzyme inhibitors or angiotensin II receptor antagonists may be at risk for severe hypotension and renal insufficiency. Although this has not been found in studies of this product, this effect should be taken into account when used.

Renal impairment and kidney transplantation: Regular monitoring of serum potassium, creatinine, and uric acid is recommended when using this product in patients with renal impairment. There is no experience with the use of this product in patients who have recently undergone kidney transplantation. Patients with severe renal insufficiency (creatinine clearance < 30ml/min) (see contraindication) should not use this product. Azotemia associated with thiazide diuretics may occur in patients with renal impairment. For those with renal insufficiency with creatinine clearance ≥30ml/min, no dose adjustment is required. However, it should be used with caution in patients with mild to moderate renal impairment (creatinine clearance ≥30ml/min but < 60ml/min).

Liver function impairment: In patients with liver function impairment, the use of thiazide diuretics should be cautious because minor changes in fluid and electrolyte balance may trigger hepatic coma. There is no experience of using this compound in patients with liver function impairment.

Aortic and mitral stenosis, hypertrophic obstructive cardiomyopathy: As with other vasodilators, this product should be used with caution in patients with aortic and mitral stenosis and hypertrophic obstructive cardiomyopathy.